杭州凯尔达焊接机器人股份有限公司 董事及高级管理人员离职管理制度 第一章 总则 第一条 为进一步完善杭州凯尔达焊接机器人股份有限公司（以下简称"公 司"）董事及高级管理人员的离职管理，保障公司治理稳定性及股东合法权益， 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司章 程指引》《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上 市公司自律监管指引第 1 号——规范运作》等有关法律法规、规范性文件及 《杭州凯尔达焊接机器人股份有限公司章程》（以下简称"《公司章程》"）， 特制定本离职管理制度。 第二条 本制度适用于公司全体董事（含独立董事）及高级管理人员的主动 辞职、任期届满离任、被解除职务以及其他导致董事、高级管理人员实际离职 等情形。 第二章 离职情形与生效条件 第八条 离职董事、高级管理人员辞职生效或者任期届满，应向董事会办妥 所有移交手续，其对公司和股东承担的忠实义务，在任期结束后并不当然解除， 在任期结束后 1 年内仍然有效。董事在任职期间因执行职务而应承担的责任， 不因离任而免除或者终止。 第九条 离职董事、高级管理人员持有公司股份的，按照公司《董事、高级 管理人员、核 ...

证券代码：688255 证券简称：凯尔达 公告编号：2025-047 杭州凯尔达焊接机器人股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2025 年 9 月 30 日（星期二）至 10 月 14 日（星期二）16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 sec@kaierda.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 杭州凯尔达焊接机器人股份有限公司（以下简称"公司"）已于 2025 年 8 月 5 日发布公司《2025 年半年度报告》，为便于广大投资者更全面深入地了解公 司 2025 年半年度经营成果、财务状况等，公司计划于 2025 年 10 月 15 日（星期 三）13:00-14:00 举行 2025 年半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 三、参加人员 会议召开时间：2025 年 10 月 15 日（星期三）13:00-14:00 会议召开地点 ...

北京市中伦律师事务所 关于杭州凯尔达焊接机器人股份有限公司 2025 年第一次临时股东大会的 法律意见书 致：杭州凯尔达焊接机器人股份有限公司 北京市中伦律师事务所（以下简称"本所"）作为杭州凯尔达焊接机器人股 份有限公司（以下简称"公司"）的常年法律顾问，受公司委托，指派律师出席 公司 2025 年第一次临时股东大会（以下简称"本次股东大会"）。本所律师根据 《中华人民共和国公司法》（以下简称"《公司法》"）等相关法律、法规、规范性 文件及《杭州凯尔达焊接机器人股份有限公司章程》（以下简称"《公司章程》"）、 《杭州凯尔达焊接机器人股份有限公司股东大会议事规则》（以下简称"《股东大 会规则》"）的规定，对本次股东大会进行见证并出具法律意见。 本所及经办律师依据《证券法》《律师事务所从事证券法律业务管理办法》 和《律师事务所证券法律业务执业规则》等规定及本法律意见书出具日以前已经 发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和诚实信用原则， 进行了充分的核查验证，保证本法律意见所认定的事实真实、准确、完整，所发 表的结论性意见合法、准确，不存在虚假记载、误导性陈述或者重大遗漏，并承 担相应法律责任。 ...

2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 证券代码：688255 证券简称：凯尔达 公告编号：2025-045 杭州凯尔达焊接机器人股份有限公司 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 9 月 16 日 （二） 股东大会召开的地点：浙江省杭州市萧山区长鸣路 778 号杭州凯尔达焊 接机器人股份有限公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 42 | | --- | --- | | 普通股股东人数 | 42 | | 2、出席会议的股东所持有的表决权数量 | 49,930,577 | | 普通股股东所持有表决权数量 | 49,930,577 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 46.9097 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） ...

证券代码：688255 证券简称：凯尔达 公告编号：2025-046 杭州凯尔达焊接机器人股份有限公司 第四届董事会第十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 杭州凯尔达焊接机器人股份有限公司（以下简称"公司"）第四届董事会第 十一次会议于 2025 年 9 月 16 日以现场结合通讯方式在公司会议室召开。经与会 董事一致同意豁免本次会议的通知时限。会议应出席董事 9 人，实际出席董事 8 人，董事足立恭雄先生委托董事侯润石先生代为出席并表决，公司全体高级管理 人员列席会议，会议由董事长侯润石先生召集主持。本次会议的召集、召开及表 决程序符合《中华人民共和国公司法》（以下简称"《公司法》"）等法律、行 政法规、部门规章和《公司章程》的有关规定。 二、董事会会议审议表决情况 表决结果：同意 9 票，反对 0 票，弃权 0 票。 2、审议通过了《关于确认审计委员会成员及召集人的议案》 根据《公司法》及《公司章程》的有关规定，董事会同意确认江乾坤先生、 倪仲夫先生、王仕凯先生为公 ...

Company Overview - Kaierda (SH 688255) announced the convening of its 11th meeting of the 4th Board of Directors on September 16, 2025, to review the proposal for establishing a "Management System for the Departure of Directors and Senior Management" [1] Financial Performance - For the fiscal year 2024, Kaierda's revenue composition is as follows: Industrial Robotics accounts for 69.16%, Industrial Welding Equipment for 23.8%, Other Businesses for 5.16%, and Other Industries for 1.87% [1] Market Position - As of the report, Kaierda's market capitalization stands at 4.2 billion yuan [1]

Group 1 - The stock price of Kailida increased by 5.19% to 37.50 CNY per share, with a trading volume of 59.04 million CNY and a turnover rate of 1.47%, resulting in a total market capitalization of 4.12 billion CNY [1] - Kailida specializes in the research, production, and sales of welding robots and industrial welding equipment, with its main business revenue composition being 68.86% from industrial robots, 23.78% from industrial welding equipment, and 7.36% from other sources [1] Group 2 - The Huaxia CSI Robotics ETF (562500) entered the top ten circulating shareholders of Kailida in the second quarter, holding 1.49 million shares, which accounts for 1.36% of the circulating shares, resulting in an estimated floating profit of approximately 2.76 million CNY [2] - The Huaxia CSI Robotics ETF has a total scale of 14.47 billion CNY and has achieved a year-to-date return of 33.79%, ranking 1246 out of 4222 in its category, with a one-year return of 88.73%, ranking 740 out of 3804 [2]

Core Viewpoint - The financial performance and trading activity of Kailida Robotics indicate a mixed outlook, with a decline in revenue and net profit, while financing activities remain at a relatively high level [1][2]. Group 1: Financial Performance - As of June 30, 2025, Kailida reported a revenue of 316 million yuan, a year-on-year decrease of 1.81% [2]. - The net profit attributable to shareholders was 2.365 million yuan, reflecting a significant year-on-year decline of 89.94% [2]. - Cumulative cash dividends since the company's A-share listing amount to 107 million yuan, with 67.51 million yuan distributed over the past three years [2]. Group 2: Shareholder and Market Activity - As of September 15, 2023, Kailida's stock price increased by 1.05%, with a trading volume of 92.748 million yuan [1]. - The financing buy-in on that day was 16.272 million yuan, while the financing repayment was 15.606 million yuan, resulting in a net financing buy-in of 666,800 yuan [1]. - The total financing and securities balance reached 177 million yuan, accounting for 4.52% of the circulating market value, which is above the 70th percentile of the past year [1]. Group 3: Shareholder Structure - As of June 30, 2025, the number of Kailida shareholders was 7,278, a decrease of 14.18% from the previous period [2]. - The average number of circulating shares per shareholder increased by 82.61% to 15,094 shares [2]. - Among the top ten circulating shareholders, Huaxia CSI Robotics ETF is the fifth largest, holding 1.4928 million shares as a new shareholder [2].

证券日报网讯 9月15日晚间，凯尔达发布公告称，控股子公司杭州凯维力传感科技有限公司近期获得1 项国家知识产权局颁发的发明专利证书，专利名称为"可自校准的SOI基MEMS三维力传感器及其制备工 艺"。 （文章来源：证券日报） ...

Group 1 - Yihau New Materials plans to reduce its shareholding by up to 1% of the company's total shares, amounting to 165,500 shares, due to personal funding needs [1] - Fuxing Pharmaceutical's subsidiary has received approval for a new indication for its drug, which is used in the treatment of certain types of breast cancer [1][2] - Shantui Co. has submitted its H-share issuance application to the China Securities Regulatory Commission, which has been accepted [3] Group 2 - Sierte's chairman plans to increase his shareholding by an amount between 3 million to 6 million yuan [4] - Borui Pharmaceutical's BGM0504 tablet has received approval for clinical trials in overweight and obese adults [5] - Ganyue Expressway reported vehicle toll service revenue of 349 million yuan for August [6] Group 3 - Chip Microelectronics has submitted its H-share issuance application to the China Securities Regulatory Commission, which has been accepted [7] - Lingrui Pharmaceutical's director plans to reduce his shareholding by up to 200,000 shares, representing 0.0353% of the total shares [8] - Jiahu Energy has adjusted its share repurchase price limit to 11.63 yuan per share [10] Group 4 - Spring Airlines reported a year-on-year increase of 12.23% in passenger turnover for August [11] - Kaida has received an invention patent for a self-calibrating sensor technology [12] - Chuanheng Co. has obtained a new utility model patent aimed at improving industrial waste utilization [14] Group 5 - Huashi Technology received a government subsidy of 2.21 million yuan, accounting for 22.71% of its latest audited net profit [15] - Shanghai Pharmaceuticals' controlling shareholder plans to increase its H-share holdings by up to 74 million shares [16] - Hongrun Construction has won a bid for a significant segment of the Shanghai Metro Line 21 project, valued at 126 million yuan [18] Group 6 - Sanfangxiang plans to invest 100 million yuan to establish a wholly-owned subsidiary focused on green technology [19] - Lao Fengxiang's subsidiaries plan to jointly invest in luxury goods sales and gold refining companies [20][21] - China Eastern Airlines reported an 8.72% year-on-year increase in passenger turnover for August [22] Group 7 - Inner Mongolia First Machinery has signed a railway freight car procurement contract worth 186 million yuan [22] - Jiuqiang Bio has received five invention patents related to diagnostic reagents [24] - Longmag Technology plans to invest 210 million yuan in its second phase project in Vietnam [25] Group 8 - Galaxy Magnetics plans to acquire 100% equity of Kyoto Longtai, with its stock suspended for trading [26] - Jinlong Co.'s controlling shareholder will have 30 million shares auctioned [27] - Haishi Co.'s controlling shareholder has released the pledge on 29.97 million shares [28] Group 9 - Qiu Tianwei plans to reduce its shareholding by up to 1.17% of the total shares [29] - Xiaocheng Technology's directors plan to reduce their shareholding by a total of 0.08% [30] - Victory Co. reported that Sunshine Life Insurance has reduced its shareholding by 4.4 million shares [31] Group 10 - Xindong Technology plans to distribute a cash dividend of 0.156 yuan per share [32] - Huaqin Technology plans to distribute a cash dividend of 0.13 yuan per share [33] - Kexing Pharmaceutical's controlling shareholder intends to transfer 5% of the company's shares [35] Group 11 - Guojin Securities has completed the repayment of its second short-term financing bond for 1.0205 billion yuan [38] - Chunhui Intelligent Control's application for asset acquisition has been accepted by the Shenzhen Stock Exchange [39] - Chaohongji has submitted its H-share issuance application to the Hong Kong Stock Exchange [40] Group 12 - Tianyue Advanced has fully exercised its over-allotment option, involving 716,180 H-shares [40] - Chengfeng Technology's vice president has resigned due to internal adjustments [41] - Yingpais plans to establish a 100 million yuan technology sports industry investment fund [43]